Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 5NIH 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 2Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Depsipeptides × Clear all
NCT00426764 2020-02-11

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

Celgene

Phase 2 Completed
131 enrolled 16 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00106418 2019-11-18

A Research Study for Patients With Prostate Cancer

Celgene

Phase 2 Completed
35 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Celgene

Phase 2 Completed
102 enrolled 15 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT00379639 2019-10-30

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Celgene

Phase 1 Completed
36 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡